Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

Commitments and Contingencies (Details) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 03, 2020 USD ($) milestone	Sep. 24, 2018 USD ($) milestone therapy	Jul. 31, 2019 USD ($)	Aug. 31, 2017 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 unit $ / shares	Jun. 22, 2021 USD ($)	Jun. 09, 2021 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Aug. 31, 2019 USD ($)
Operating Leased Assets [Line Items]
General and administrative						$ 21,832	$ 17,418
Proceeds from sale						5,398	6,699
Royalty agreement, payment received			$ 2,000
Period after public launch to terminate agreement			3 years
Buyout option, percentage of net present value of royalty payments			75.00%
Aevi
Operating Leased Assets [Line Items]
Payment for contingent consideration						0
Aevi
Operating Leased Assets [Line Items]
Number of contingent consideration milestones \| milestone	2
Contingent consideration	$ 6,500				$ 6,500
Ichorion
Operating Leased Assets [Line Items]
Number of contingent consideration milestones \| milestone		3
Contingent consideration		$ 15,000
Payment for contingent consideration						0
Milestone One \| Aevi
Operating Leased Assets [Line Items]
Contingent consideration	2,000
Milestone One \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration		6,000
Milestone Two \| Aevi
Operating Leased Assets [Line Items]
Contingent consideration	$ 4,500
Milestone Two \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration		5,000
Milestone Three \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration		$ 4,000				0
License revenue
Operating Leased Assets [Line Items]
Proceeds from sale				$ 25,000		625	$ 0
CERC-801, CERC-802, And CERC-803 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy		3
CERC-913 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy		1
TRIS Pharma \| Karbinal Agreement
Operating Leased Assets [Line Items]
Minimum quantity required \| unit								70,000
Make whole payment per unit (in dollars per share) \| $ / shares								$ 30
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Operating Leased Assets [Line Items]
Upfront license fee												$ 10,000
Percent of payments received from sublicensing												30.00%
Research and development						10,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment												$ 112,500
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment												$ 75,000
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Operating Leased Assets [Line Items]
Upfront license fee						500
Maximum aggregate milestone payment						5,500
Research and development						500
Cumulative expense recognized to date						500
AstraZeneca plc (AstraZeneca) \| AVTX-007 AstraZeneca License Agreement
Operating Leased Assets [Line Items]
Upfront license fee						6,000
Research and development						0
Cumulative expense recognized to date						1,500
AstraZeneca plc (AstraZeneca) \| AVTX-007 AstraZeneca License Agreement \| Milestone One
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment						71,500
AstraZeneca plc (AstraZeneca) \| AVTX-007 AstraZeneca License Agreement \| Milestone Two
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment						90,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement
Operating Leased Assets [Line Items]
Upfront license fee									$ 400
Research and development						400
Cumulative expense recognized to date						0
Patent costs									500
General and administrative						500
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone One
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment									24,200
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone Two
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment									$ 50,000
Alto \| AVTX-301 Out-License
Operating Leased Assets [Line Items]
Maximum proceeds from milestones											$ 18,600
Revenue recognized from milestones to date						0
ES \| AVTX-406 License Assignment
Operating Leased Assets [Line Items]
Revenue recognized from milestones to date						0
ES \| AVTX-406 License Assignment \| Milestone One
Operating Leased Assets [Line Items]
Maximum proceeds from milestones										$ 6,000
ES \| AVTX-406 License Assignment \| Milestone Two
Operating Leased Assets [Line Items]
Maximum proceeds from milestones										$ 20,000
ES \| AVTX-611 License Assignment
Operating Leased Assets [Line Items]
Maximum proceeds from milestones													$ 20,000
Janssen Pharmaceuticals, Inc. (Janssen) \| AVTX-501
Operating Leased Assets [Line Items]
Maximum proceeds from milestones				$ 20,000
Revenue recognized from milestones to date						$ 0